Investigation of correlation between antitumor effect of combined lapatinib/capecitabine therapy and p95HER2, PTEN and PIK3CA in patients with HER2 positive breast cancer - Lapatinib biomarker study(KBC-SG 1107)

Kyushu Breast Cancer Study Group0 个研究点目标入组 200 人开始时间: 2012年1月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Pregnant or lactation women, or women with suspected pregnancy 2.Patients who suffer malabsorption syndrome or disease affecting gastro intestinal function, or resection or stomach or small intestine, or ulcerative colitis 3.Coexistence malignant tumor other than breast cancer or a history of such tumor within 5 years of the beginning of this study 4.Patients who has not recovered from previous cancer treatment to less than G1 toxicity 5.Previous or current history of interstitial pneumonia 6.Active or poorly controlled infectious diseases 7.Severe psychiatric disorder 8.Poorly controlled or symptomatic angina pectoris, arrhythmia or congestive heart failure 9.Symptomatic CNS metastasis 10.Meningitis carcinomatosa 11.History of immediate or delayed hypersensitivity reaction to the compounds similar to both capecitabine and lapatinib 12.Patients judged by the investigator to be unfit for the study

发起方

Kyushu Breast Cancer Study Group